Globus Medical (GMED) PT Raised to $103 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Truist Securities Reiterates Hold Rating on Globus Medical (GMED)
February 24, 2025 2:46 PM ESTTruist Securities analyst Richard Newitter reiterated a Hold rating and $90.00 price target on Globus Medical (NYSE: GMED)
The analyst comments "GMED's relatively broad/clean 4Q beat was somewhat clouded by ongoing q's re: the unexpected NVRO deal (announced 2/6 [HERE]). We think... More
